Citi maintained a Buy rating on Biogen (NASDAQ: BIIB) and raised its price target to $320.00 (from $260.00). The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE